The main pharmacological action of the active ingredient in Fluconix-340, nitroxinil, is fasciolicidal. The lethal action against Fasciola hepatica has been demonstrated in vitro and in vivo in laboratory animals, and in sheep and cattle. The mechanism of action is due to uncoupling of oxidative phosphorylation. It is also active against triclabendazole-resistant F. hepatica.
Fluconix-340 is indicated for the treatment of fascioliasis (infestations of mature and immature Fasciola hepatica) in cattle and sheep. It is also effective, at the recommended dose rate, against adult and larval infestations of Haemonchus contortus in cattle and sheep and Haemonchus placei, Oesophagostomum radiatum and Bunostomum phlebotomum in cattle.
Do not use in animals with known hypersensitivity to the active ingredient.
Do not use in animals producing milk for human consumption.
Do not exceed stated dose.
Small swellings are occasionally observed at the injection site in cattle. These can be avoided by injecting the dose in two separate sites and massaging well to disperse the solution. No systemic ill effects are to be expected when animals (including pregnant cows and ewes) are treated at normal dosage.
Special precautions:
Ensure the injection does not enter subcutaneous muscle. On farms with fluke-infested pastures, routine preventative dosing should be carried out at intervals of not less than one month, having regard for such factors as the past disease history of the farm, the frequency and severity of neighbouring outbreaks and regional forecasts or incidence.